Inaktiver Wert

Andere Sprachen Theravance Inc Nasdaq

Aktien

US88338T1043

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

24.04.	Die Tochtergesellschaft von Innoviva, Inc., Innoviva Specialty Therapeutics, Inc., gibt positive Daten aus der oralen Phase-3-Studie mit Zoliflodacin zur Behandlung von unkomplizierter Gonorrhoe auf der ESCMID Global 2024 bekannt	CI
04.03.	Armata Pharmaceuticals sichert sich $35 Millionen Kreditvertrag von Innoviva Unit	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	25.04.
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24.04.
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24.04.
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	04.03.
North American Morning Briefing : Stock Futures -2-	04.03.
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	29.02.
Innoviva: Q4 Earnings Snapshot	29.02.
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	29.02.
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	29.02.
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29.02.
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	06.02.
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	06.02.
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	17.11.
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	02.11.
Innoviva: Q3 Earnings Snapshot	01.11.
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	01.11.
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01.11.
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress	01.11.
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	01.11.
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Theravance Inc Nasdaq

Aktien

US88338T1043

Andere Sprachen

Filter